Innovent Biologics and Daiichi Sankyo have entered an exclusive agreement under which Innovent will commercialize VANFLYTA, or quizartinib, in Mainland China, adding a recently approved targeted therapy for newly diagnosed FLT3-ITD-positive acute myeloid leukemia to Innovent’s hematology portfolio. Daiichi Sankyo will retain responsibility for development, manufacturing and supply, while Innovent receives sole commercialization rights and will lead market promotion in China.
The agreement moves VANFLYTA rapidly from regulatory approval into a different phase of the product lifecycle. China’s National Medical Products Administration approved the medicine in June 2026 in combination with standard cytarabine and anthracycline induction, followed by cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy for adults with newly diagnosed FLT3-ITD-positive AML identified with an adequate validated diagnostic test. Daiichi Sankyo described VANFLYTA at the time of approval as the first and only FLT3 inhibitor approved in China for this newly diagnosed patient setting.
For the two companies, therefore, the August agreement is less about gaining another regulatory milestone and more about whether an approved precision oncology medicine can be embedded efficiently into China’s AML treatment pathway. Innovent gains a differentiated hematology product backed by Phase 3 survival data, while Daiichi Sankyo gains a commercial partner with an existing oncology presence in China without transferring control over development or manufacturing. Financial terms, including any upfront consideration, milestones or royalty arrangements, were not disclosed in the announcement.
Why does the Innovent Biologics deal matter so soon after VANFLYTA’s China approval?
The timing is one of the more important features of the agreement. VANFLYTA received its Chinese approval on June 15, 2026, and the commercialization partnership was announced less than two months later. That compressed sequence suggests the immediate priority is to build market access and physician reach around an asset whose central regulatory risk in the approved indication has already been removed.
Under the division of responsibilities, Daiichi Sankyo continues to control areas that directly affect the medicine itself, including development, manufacturing and product supply. Innovent, meanwhile, takes the customer-facing commercial role in Mainland China. This structure allows Daiichi Sankyo to retain responsibility for the scientific and supply side of VANFLYTA while relying on Innovent’s domestic commercial infrastructure to reach hematologists and treatment centres.
Innovent said VANFLYTA will become the 20th product in its commercial portfolio. The company already markets several oncology and hematology medicines, giving the partnership a potentially useful degree of commercial overlap rather than requiring a new sales organisation to be constructed around a single AML product. The practical value of that infrastructure, however, will ultimately be measured by penetration into the specialist centres that diagnose and treat intensive-therapy-eligible AML patients, not simply by the size of Innovent’s portfolio.
The agreement also illustrates how licensing and commercialization partnerships can differ from conventional drug-development licensing transactions. Innovent is not acquiring VANFLYTA’s development programme or manufacturing rights. It is effectively becoming the exclusive commercialization engine for China, meaning Daiichi Sankyo retains substantial control over the underlying asset while Innovent assumes responsibility for converting regulatory approval into routine commercial use.
What did QuANTUM-First actually establish about quizartinib in newly diagnosed FLT3-ITD AML?
VANFLYTA’s Chinese approval is supported by QuANTUM-First, a global randomized, double-blind, placebo-controlled Phase 3 trial enrolling 539 adults aged 18 to 75 with newly diagnosed FLT3-ITD-positive AML. Patients were assigned to quizartinib or placebo alongside standard induction and consolidation therapy, with the assigned study drug then continued as maintenance after consolidation.
The study’s primary endpoint was overall survival, giving the evidence package more clinical weight than one built primarily around response rate or another intermediate endpoint. Median overall survival was 31.9 months in the quizartinib group compared with 15.1 months in the placebo group, corresponding to a hazard ratio of 0.78 and a statistically significant reduction in the risk of death during the study observation period.
An important nuance is that the complete remission rate itself was 55% in both groups in the United States Food and Drug Administration’s review of the trial. The difference was more visible in the durability of remission and overall survival, with median duration of complete remission reported at 38.6 months with quizartinib versus 12.4 months with placebo. That distinction matters because the case for quizartinib is not that it simply drove substantially more patients into initial complete remission, but that adding sustained FLT3 inhibition across the treatment sequence was associated with longer survival.
The United States Food and Drug Administration approved VANFLYTA for the same newly diagnosed FLT3-ITD-positive AML setting in July 2023, and Daiichi Sankyo said in June 2026 that the drug was approved across more than 35 countries and regions for the newly diagnosed indication. China therefore represents an expansion of an established global regulatory programme rather than the first commercial validation of the treatment strategy.
Why could FLT3-ITD testing become as important commercially as the VANFLYTA launch itself?
VANFLYTA is not an undifferentiated AML therapy. Its Chinese label requires newly diagnosed disease with confirmed FLT3-ITD positivity using an adequate validated diagnostic test. That means the eligible commercial population is defined molecularly before quizartinib enters the treatment pathway.
FLT3 mutations are among the most common molecular alterations identified in AML, and FLT3-ITD accounts for the majority of FLT3 mutations. Daiichi Sankyo cited estimates suggesting that FLT3-ITD mutations occur in approximately one-quarter of AML cases and are associated with increased relapse risk and shorter survival. The addressable population is therefore clinically meaningful, but it still represents a molecularly selected subgroup rather than the entire Chinese AML market.
From a commercialization perspective, this makes diagnostic execution integral to drug adoption. Hospitals need the ability to identify FLT3-ITD status sufficiently early for the result to influence induction-treatment planning. A commercial strategy focused only on drug awareness would miss part of the pathway because physicians cannot use the medicine within its approved indication without establishing the biomarker status.
This is also where Innovent’s role could extend beyond conventional promotion. A successful launch will depend on reaching hematology centres that already perform molecular profiling, supporting awareness of the approved treatment pathway and ensuring that eligible patients can be identified during the compressed decision-making window that accompanies newly diagnosed AML. The requirement does not necessarily create a disadvantage for VANFLYTA, but it means market penetration will be closely linked to the consistency and speed of diagnostic testing.
How does VANFLYTA fit into China’s expanding FLT3-targeted AML treatment landscape?
FLT3 inhibition is not entirely new to Chinese AML care. Astellas Pharma’s gilteritinib received conditional Chinese approval in 2021 for adults with relapsed or refractory AML carrying a FLT3 mutation. VANFLYTA’s differentiation in China is its approval in the newly diagnosed FLT3-ITD-positive setting as part of an intensive chemotherapy and maintenance strategy.
That distinction is clinically and commercially important. Relapsed or refractory AML represents a different treatment setting from first-line intensive therapy, while quizartinib’s approved regimen begins during induction and can extend through consolidation and subsequent maintenance. The commercial opportunity is therefore tied to VANFLYTA becoming incorporated into an extended treatment sequence rather than competing only as a later-line rescue therapy.
Quizartinib is a selective type II FLT3 inhibitor targeting FLT3-ITD. The broader international FLT3 field includes drugs such as midostaurin and gilteritinib, but differences in mutation coverage, approved treatment setting, regimen design and jurisdiction mean simple drug-to-drug comparisons can be misleading. VANFLYTA’s China proposition should be assessed against its exact approval, namely newly diagnosed FLT3-ITD-positive AML treated with intensive chemotherapy followed by the specified maintenance approach.
This specificity may also work commercially in Innovent’s favour. Rather than promoting quizartinib across a vaguely defined AML population, the sales and medical strategy can focus on a clearly identifiable molecular subgroup with Phase 3 overall survival evidence and a newly established Chinese label.
What safety and implementation requirements could influence VANFLYTA uptake in China?
Commercial adoption will also depend on how effectively treatment centres manage VANFLYTA’s safety requirements. Daiichi Sankyo reported that among 268 quizartinib-treated patients assessed in the pivotal programme, commonly reported grade 3 or 4 adverse reactions included decreased platelet count, decreased haemoglobin, decreased neutrophil count and increased alanine aminotransferase. QT prolongation is another clinically important consideration associated with quizartinib.
The United States label carries a boxed warning concerning QT prolongation, torsades de pointes and cardiac arrest, and the United States Food and Drug Administration requires VANFLYTA to be distributed through a Risk Evaluation and Mitigation Strategy in that market. Those United States requirements should not be assumed to apply identically in China, where prescribing and monitoring must follow the local approved label, but they demonstrate why cardiac monitoring, electrolyte management and appropriate patient selection are important parts of quizartinib implementation.
The June China approval announcement reported QTcF values above 500 milliseconds in 2.3% of VANFLYTA-treated patients, while 0.8% discontinued because of QT prolongation. It also reported two cardiac arrest events with recorded ventricular fibrillation, one fatal, both in the setting of severe hypokalaemia. Those findings do not erase the overall survival benefit demonstrated in QuANTUM-First, but they reinforce that commercialization of VANFLYTA is inseparable from specialist treatment infrastructure and appropriate safety monitoring.
For Innovent, the commercial task is consequently more sophisticated than introducing a conventional outpatient oncology medicine. VANFLYTA sits inside a multi-stage AML treatment pathway involving induction chemotherapy, consolidation, potential transplantation and maintenance, with molecular testing and safety monitoring at different stages.
Can Innovent Biologics turn regulatory approval into meaningful VANFLYTA adoption in China?
The strongest element of the partnership is the fit between the two companies’ roles. Daiichi Sankyo brings an already approved medicine supported by a randomized Phase 3 overall survival result and remains responsible for development, manufacturing and supply. Innovent brings a China-focused oncology and hematology commercial organisation and says VANFLYTA expands its marketed portfolio to 20 products.
What the agreement does not establish is the eventual scale or speed of uptake. No sales target, launch revenue forecast, pricing arrangement or financial terms between the companies were disclosed. Regulatory approval also does not automatically determine reimbursement, hospital formulary access or the pace at which prescribing behaviour changes.
The next meaningful test will therefore be execution rather than another clinical headline. Innovent will need to translate the QuANTUM-First evidence into specialist physician awareness, support identification of FLT3-ITD-positive patients and navigate the practical market-access requirements surrounding a newly approved targeted AML regimen. Daiichi Sankyo, meanwhile, must maintain dependable supply and continue managing the broader clinical development programme.
VANFLYTA enters that commercial phase with an unusually clear proposition: a defined biomarker population, a Phase 3 overall survival endpoint, a recent Chinese approval and an experienced domestic commercialization partner. The unresolved question is no longer whether quizartinib can cross China’s regulatory threshold. It is whether Innovent Biologics and Daiichi Sankyo can turn that approval into consistent molecular testing, treatment-centre adoption and sustained access for eligible patients across Mainland China.
